

QUALITY OF LIFE STUDY: GALCANEZUMAB IN THE TREATMENT OF MIGRAINE

E.M. BARREIRO FERNANDEZ¹, E. RIOS- SANCHEZ¹, C.M. DOMINGUEZ-SANTANA¹, C. MORENO-RAMOS¹, M.D. GIL-SIERRA¹.
¹HOSPITAL UNIVERSITARIO PUERTO REAL, SERVICIO DE FARMACIA, CADIZ, SPAIN

➤ Background and importance

Galcanezumab is a monoclonal antibody used for migraine prevention. Its approval was based on demonstrated efficacy through reduction of migraine days and impact on quality of life. However, this last variable isn't routinely monitored in real practice.

➤ Aim and objectives

To determine the improvement of the quality of life the patients with migraine in treatment with galcanezumab and correlated with effectiveness in real practice.

➤ Material and methods

STUDY DESIGN

- Prospective study
- February 2020 to September 2021

QUALITY OF LIFE

- Rol restrictive-RR (7 ítems)
- Rol emotional-RE (3 ítems)
- Rol preventive-RP (4 ítems)

Response RR domain: Change from baseline to week 12 ≥ 17 points according to trials.

Questionnaire version 2.1(MSQ)

SCORE (0-100)
Week 0,4,12

EFFECTIVINESS

- Number of episodes per month
- Discontinued treatment


Response: Change from baseline $\geq 25\%$ migraine days

➤ Results

POPULATION


30 patients
90% ♀
73% chronic migraine
27% episodic migraine
Treatment duration:
10 months (4-18)

QUALITY OF LIFE



EFFECTIVINESS

MEDIAN NUMBER EPISODES



13% PATIENTS
DISCONTUNUED TREATMENT
33% REDUCED ≥ 25 MIGRAINE DAYS

➤ Conclusion and relevance

1. After 12 weeks, only 17% patients obtained response for RR domain; and even, 1 of 4 patients worsening quality of life.
2. Effectiveness obtained in few patients be correlated with quality of life . Therefore, quality of life questionnaires should be one more tool to evaluate treatment effectiveness.